Maria Belvisi

我对呼吸科学的热情始于大学时代. I was fascinated with how the respiratory system interacts with immune and environmental triggers. In normal lungs these triggers are protective but in patients with chronic lung disease these can become harmful and contribute to increased troublesome symptoms. It was clear then that there were significant therapeutic needs in these patients that were not addressed by the current treatments. 作为一个呼吸药理学家, my proudest achievements are therefore working on two therapeutic agents which are now used in the treatment of asthma and COPD. 尽管已经取得了重大进展, we still need to work on not just the treatment of chronic lung disease but also on disease modification and cure.

2017年9月，我加入澳门在线赌城娱乐的biopharmacics R&D组以呼吸道、炎症为主 & Autoimmunity research. 我在哥德堡工作, Sweden, 澳门在线赌城娱乐三大战略研发中心之一, 这里也是该公司早期呼吸系统研究的所在地. 以我作为高级副总裁和早期呼吸系统主管的身份, 炎症与自身免疫(RIA), I lead early-stage research and development in chronic diseases of the lung – such as asthma, 慢性阻塞性肺病(COPD), 特发性肺纤维化(IPF)和慢性咳嗽. 澳门第一赌城在线娱乐专注于三个领域:肺上皮，肺免疫和肺再生. I am really enjoying being part of the Respiratory team at AstraZeneca because it has given me the opportunity to work alongside inspiring scientists, and within a global organisation that has the expertise and capacity needed to drive science towards new medicines for patients.

除了我在澳门在线赌城娱乐的角色, I am Professor of Respiratory Pharmacology and Head of the Respiratory Pharmacology Group at Imperial College London. 我的研究重点是哮喘的细胞和分子机制, COPD and chronic cough, 目的是开发治疗这些疾病的方法. I enjoy helping to drive the research efforts here and to be part of training the next generation of respiratory scientists.

I was research director for the European Respiratory Society (ERS) from 2013 to 2016, 我曾在几家科学期刊的编辑委员会任职, 包括《美国呼吸杂志 Critical Care Medicine, 欧洲呼吸杂志 and executive editor of 药理学和治疗学. 我写了大量关于呼吸系统疾病和治疗的文章, with many of my papers being cited by peers and referenced in other publications. 我也是英国药理学学会的当选会员, 欧洲呼吸学会和医学科学院.

My experience in industry includes leading a team at Rhône-Poulenc Rorer (now Aventis Pharma) focused on respiratory disease. In 2010, 我还和同事一起开了自己的公司, Dr Mark Birrell, called IR Pharma, 呼吸药理学临床前药物研发组织.